Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of SHR-1501 combined with adebrelimab in advanced or metastatic malignant tumors
CTR20252806Phase 2Active
- Sponsor
- Hengrui Therapeutics
- Start
- Aug 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of SHR-1501 and adebrelimab in Nonhematologic neoplasms, sponsored by Hengrui Therapeutics. Primary endpoints: Dose-limiting toxicity incidence, Adverse events and serious adverse events and 3 more. Started Aug 2025; status: active.
02
Drugs
SHR-1501adebrelimab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20252806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252806.